New inhaled drug tested in healthy volunteers for lung scarring disease

NCT ID NCT06746064

Completed Knowledge-focused Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested the safety and how the body handles an inhaled drug called CHF10073 in 155 healthy volunteers. The drug is being developed for pulmonary fibrosis, a serious lung-scarring condition. The trial looked at different single and multiple doses, and also checked how another drug (itraconazole) affects CHF10073 levels. Since this is a Phase 1 study in healthy people, it does not test if the drug actually treats the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CHF10073 (inhaled drug)
What this could lead to: If successful, this could support further testing of CHF10073 as a potential treatment for pulmonary fibrosis.
What could go wrong: This is a very early Phase 1 study in healthy people, not patients. It only checks safety and drug levels, not whether the drug works for the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY FIBROSIS

Contacts and locations

Locations

SGS Belgium NV Clinical Pharmacology Unit

Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.